EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cilostazol Treatment for Intracerebral Hemorrhage: Targeting Dural Lymphatics

Chen-Kai Lan, Wan-Ru Chen iD, Yung Chia Hsieh, Tze-Yen Lin, Shao-Chun Hsu iD, Zi-Rou Jiang, Shih-Pin Chen iD, Danye Jiang iD, Louise D McCullough iD, Jaroslaw Aronowski iD, Li-Kai Tsai iD, Hsin-Hsi Tsai iD und 1 weitere

Stroke · 2026-10 · 57 (10) · 3091-3105

DOI: 10.1161/strokeaha.126.055192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke, 2026-10. Verfasst von Chen-Kai Lan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department and Graduate Institute of Physiology, National Taiwan University College of Medicine, Taipei (C.-K.L., W.-R.C., Y.C.H., T.-Y.L., C.-F.C.). Hauptthemen laut MEDLINE: Cilostazol, Cerebral Hemorrhage, Dura Mater, Lymphatic System. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The meningeal lymphatic system contributes to hematoma resolution and neurological recovery after intracerebral hemorrhage (ICH). We previously demonstrated that intraperitoneal cilostazol administration promotes dural lymphatic growth and enhances clearance of intracerebrally injected red blood cells; however, the antiplatelet effects of cilostazol raise safety concerns in ICH, potentially limiting clinical translation. Here, we evaluated whether oral cilostazol at clinical-equivalent doses in mice enhances dural lymphatic function and improves outcomes after ICH. METHODS: ICH was induced by collagenase injection to model microvascular rupture. Cilostazol was orally administered to ICH mice at clinically equivalent doses, given at different time points and for varying durations. Prolymphangiogenic effects of cilostazol were examined in healthy in vivo and ex vivo meninges. Flow cytometry and immunofluorescence were performed to assess lymphatic endothelial cell proliferation and dural lymphatic remodeling. Lymphatic function was evaluated by in vivo live imaging and histological analysis of fluorescent tracer drainage. Short- and long-term histopathologic and behavioral outcomes were also evaluated. RESULTS: Oral cilostazol treatment initiated either 3 hours or 3 days after ICH enhanced dural lymphatic coverage and function, accompanied by reduced hematoma volume, neuronal injury, synapse loss, and long-term neurological deficits. Cilostazol increased CD31 + PDPN + lymphatic endothelial cells in ex vivo meninges, induced dural lymphatic hyperplasia, and enhanced lymphatic drainage in healthy mice. Both pretreatment and delayed treatment of cilostazol did not increase hematoma volume but rather improved ICH outcomes. CONCLUSIONS: By promoting dural lymphatic remodeling and drainage, cilostazol facilitates hematoma resolution and neurological recovery after ICH. Cilostazol treatment does not exacerbate initial bleeding or provoke hematoma expansion in the experimental ICH. These findings support clinical translation and provide mechanistic and dosing rationale for an ongoing phase II randomized trial (URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06504576).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CilostazolCerebral HemorrhageDura MaterLymphatic SystemAnimalsMiceMaleTetrazolesMice, Inbred C57BL

Stichwörter der Autor:innen

cerebral hemorrhagecilostazolhematomahemorrhagic strokelymphatic systemtranslational science

Substanzen

CilostazolTetrazoles

Autor:innen und Institutionen

  • Department and Graduate Institute of Physiology, National Taiwan University College of Medicine, Taipei (C.-K.L., W.-R.C., Y.C.H., T.-Y.L., C.-F.C.).
  • School of Medicine, National Taiwan University College of Medicine, Taipei (W.-R.C.).
  • Department of Medical Education (Y.C.H.), National Taiwan University Hospital, Taipei.
  • Imaging Core, National Taiwan University College of Medicine, Taipei (S.-C.H.).
  • Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan (Z.-R.J., S.-P.C.).
  • Brain Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan (S.-P.C.).

ORCID-Profile: Wan-Ru Chen, Shao-Chun Hsu, Shih-Pin Chen, Danye Jiang, Louise D McCullough, Jaroslaw Aronowski, Li-Kai Tsai, Hsin-Hsi Tsai, Che-Feng Chang

Förderung

  • NINDS NIH HHS

Zitieren

APA

Lan, C. K., Chen, W. R., Hsieh, Y. C., Lin, T. Y., Hsu, S. C., Jiang, Z. R., Chen, S. P., Jiang, D., McCullough, L. D., Aronowski, J., Tsai, L. K., Tsai, H. H., & Chang, C. F. (2026). Cilostazol Treatment for Intracerebral Hemorrhage: Targeting Dural Lymphatics. Stroke, 57(10), 3091-3105. https://doi.org/10.1161/strokeaha.126.055192

Vancouver

Lan CK, Chen WR, Hsieh YC, Lin TY, Hsu SC, Jiang ZR, et al. Cilostazol Treatment for Intracerebral Hemorrhage: Targeting Dural Lymphatics. Stroke. 2026;57(10):3091-3105. doi:10.1161/strokeaha.126.055192

BibTeX
@article{Lan2026,
  author = {Lan, Chen-Kai and Chen, Wan-Ru and Hsieh, Yung Chia and Lin, Tze-Yen and Hsu, Shao-Chun and Jiang, Zi-Rou and Chen, Shih-Pin and Jiang, Danye and McCullough, Louise D and Aronowski, Jaroslaw and Tsai, Li-Kai and Tsai, Hsin-Hsi and Chang, Che-Feng},
  title = {Cilostazol Treatment for Intracerebral Hemorrhage: Targeting Dural Lymphatics},
  journal = {Stroke},
  year = {2026},
  volume = {57},
  number = {10},
  pages = {3091--3105},
  doi = {10.1161/strokeaha.126.055192}
}
Kostenlos starten →